|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
TYPE OF REPORT | 8. Year | 2017 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Thomas DiLenge |
Date | 4/20/2017 5:20:18 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Food Waste
Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
Funding for Biomass Crop Assistance Program
---Farm Bill Reauthorization
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for the USDA
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Genetically Engineered (GE) Animals
---FDA Approval
---The One Health Act (Senate Discussion Draft)
---FDA Proposed Guidance on Gene Editing
Potential Regulation of New Genetic Modification Technologies
---Review and Labeling of Food Derived From Biotechnology
---Implementation of Disclosure Law
USDA/APHIS Agricultural Biotechnology Regulations
---Potential Revisions to Part 340 Regulations
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), White House Office, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Matthew |
OMara |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Kyle |
|
|
|
Nicolas |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---FDA Approval
---The One Health Act Discussion Draft
---FDA Proposed Guidance on Gene Editing
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, Agriculture - Dept of (USDA), White House Office, Food & Drug Administration (FDA), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Jeanne |
Haggerty |
|
|
|
Sarah |
Kyle |
|
|
|
Nicolas |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Continuing Appropriations Act for FY 2017
Funding for Biofuels
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Farm Bill Reauthorization
Funding for Biomass Crop Assistance Program
---Farm Bill Reauthorization
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for Biorefineries
---Farm Bill Reauthorization
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Continuing Appropriations Act for FY 2017
Funding for FDA
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for National Institutes of Health
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Continuing Appropriations Act for FY 2017
Funding for Renewable Chemicals/Bio-based Products
---USDA BioPreferred Program
---EPA Safer Choice Program
---Farm Bill Reauthorization
---H.R. 4909/S.2943: National Defense Authorization Act (NDAA) for 2017
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Continuing Appropriations Act for FY 2017
Funding for the USDA
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kathleen |
Holcombe |
|
|
|
Phi D. |
Vu |
|
|
|
Phyllis |
Arthur |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Kyle |
|
|
|
Taylor |
Booth |
|
|
|
Nicolas |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
Funding for Renewable Chemicals/Bio-based Products
---USDA BioPreferred Program
---EPA Safer Choice Program
---Farm Bill Reauthorization
---H.R. 4909/S.2943: National Defense Authorization Act (NDAA) for 2017
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Renewable Chemicals/Bio-based Products (Non-Funding)
---Expansion of Master Limited Partnerships to Renewable Chemicals
---Farm Bill Reauthorization
---New Production Tax Credit
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
---Reauthorization of USDA Bio-Preferred Program
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Rina |
Singh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Drug Importation
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---S.469: Affordable and Safe Prescription Drug Importation Act
--S.Amdt.174 to S.Con.Res.3
---S.Amdt.178 to S.Con.Res.3
Opioid Abuse
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kathleen |
Holcombe |
|
|
|
Sarah |
Kyle |
|
|
|
Taylor |
Booth |
|
|
|
Nicolas |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Bayh-Dole Act/Tech Transfer
---March-In Rights
Intellectual Property International Enforcement
---India
---Saudi Arabia
Inter Partes Review
---Implementation of the America Invents Act of 2011
Patent Reform
---Implementation of the America Invents Act of 2011
UN High Level Commission on Access to Medicines
---IP Proposals
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Hans |
Sauer |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Sarah |
Kyle |
|
|
|
Taylor |
Booth |
|
|
|
Nicolas |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Farm Bill Reauthorization
---Production Tax Credit Extension
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
Funding for Biofuels
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Farm Bill Reauthorization
Funding for Biomass Crop Assistance Program
---Farm Bill Reauthorization
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for Biorefineries
---Farm Bill Reauthorization
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Renewable Fuel Standard
---Changes to the Point of Obligation under the RFS
---H.R. 1311/S.517: Consumer and Fuel Retailer Choice Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Rina |
Singh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Food Waste
Genetically Engineered (GE) Animals
---FDA Approval
---The One Health Act (Senate Discussion Draft)
---FDA Proposed Guidance on Gene Editing
---Review and Labeling of Food Derived From Biotechnology
---Implementation of Disclosure Law
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), White House Office, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Jeanne |
Haggerty |
|
|
|
Sarah |
Kyle |
|
|
|
Nicolas |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Farm Bill Reauthorization
---Production Tax Credit Extension
---Reauthorization of Biorefinery, Renewable Chemical, and Biobased Product Manufacturing Assistance Program
Funding for Biofuels
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Farm Bill Reauthorization
Funding for Biomass Crop Assistance Program
---Farm Bill Reauthorization
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for Biorefineries
---Farm Bill Reauthorization
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Renewable Fuel Standard
---Changes to the Point of Obligation under the RFS
---H.R. 1311/S.517: Consumer and Fuel Retailer Choice Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Rina |
Singh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
21st Century Cures Act Implementation
---Biomarkers and Regulatory Science Improvements
---Communication with Healthcare Professionals and Payors
---Expanded Access to Investigational Drugs
---Expedited Pathways
---FDA Hiring Flexibility
---FDA Management and Financial Accountability
---Government Hiring Freeze
---Innovation Incentives
---Patient-Focused Drug Development
---Priority Review Voucher Programs
---Use of Real-World Evidence
340B Drug Pricing Program
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Program Implementation & Oversight
Affordable Care Act - Repeal and Replace
---H.R. 1628: American Health Care Act
---Vaccine Issues
Antibiotic & Diagnostic Tax Credit
---H.R. 1840: Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017
Biodefense Research, Development, and Procurement Issues (Nonfunding)
---Implementation of Medical Countermeasures Innovation Act
Biosimilars
---Access to Samples for Testing
---Biosimilar User Fee Act Reauthorization and Implementation
---Coding
---Interchangeability and Pharmacy Substitution
---Naming
Drug Evaluation and Review
---Compassionate Use/Expanded Access
---Government Hiring Freeze
---Regenerative Medicine
---Implementation of the FDA Safety and Innovation Act
---RACE for Children Act (Discussion Draft)
---Reauthorization of the Prescription Drug User Fee Act
---S.204/H.R.878: Right to Try Act of 2017
Drug Importation
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---S.469: Affordable and Safe Prescription Drug Importation Act
---S.Amdt.174 to S.Con.Res.3
---S.Amdt.178 to S.Con.Res.3:
Drug Manufacturing, Quality & Distribution
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Implementation of H.R. 3204: The Drug Quality and Security Act
---Pharmacy Compounding & Oversight
---Supply Chain Integrity and Traceability
---Vial and Dose Size
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Continuing Appropriations Act for FY 2017
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Continuing Appropriations Act for FY 2017
Funding for FDA
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
Funding for National Institutes of Health
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Continuing Appropriations Act for FY 2017
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Continuing Appropriations Act for FY 2017
Generic Drug Entry
---Access to Samples for Testing
---Incentives for Generic Entry
Generic Drug Application Review Reforms
---H.R. 749: Lower Drug Costs Through Competition Act
---S. 297: Increasing Competition in Pharmaceuticals Act
Government Price Reporting
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Independent Payment Advisory Board
Medicaid Pricing and Rebates
---Average Manufacturer Price Calculations
Orphan Drug Act Tax Credit
Reimbursement for Innovative Products
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---Value-based Contracting and Communications
Turkish Requirement for Localized Drug Manufacturing
UN High Level Commission on Access to Medicines
Vaccines and Infectious Diseases
---Vaccine Injury Compensation Program
---Vaccine Safety
Combating Antibiotic-Resistant Bacteria (CARB) Initiative
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Continuing Appropriations Act for FY 2017
Drug Pricing
---S.Amdt.188 to S.Con.Res.3
---S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act
---The Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act (Senator Wyden Discussion Draft)
---Drug Price Gouging Enforcement (Senator Coons Discussion Draft)
---S. 771: Improving Access to Affordable Prescription Drugs
Opioid Abuse
Longitudinal Study of Chronic Diseases
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), U.S. Trade Representative (USTR), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kathleen |
Holcombe |
|
|
|
Phi D. |
Vu |
|
|
|
Phyllis |
Arthur |
|
|
|
Sarah |
Kyle |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Taylor |
Booth |
|
|
|
Nicolas |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development, and Procurement Issues (Nonfunding)
---Implementation of Medical Countermeasures Innovation Act
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Continuing Appropriations Act for FY 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Phi D. |
Vu |
|
|
|
Phyllis |
Arthur |
|
|
|
Sarah |
Kyle |
|
|
|
Taylor |
Booth |
|
|
|
Nicolas |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Longitudinal Study of Chronic Diseases
Biodefense Research, Development, and Procurement Issues (Nonfunding)
---Implementation of Medical Countermeasures Innovation Act
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Continuing Appropriations Act for FY 2017
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Continuing Appropriations Act for FY 2017
Funding for National Institutes of Health
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---Continuing Appropriations Act for FY 2017
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kathleen |
Holcombe |
|
|
|
Phi D. |
Vu |
|
|
|
Phyllis |
Arthur |
|
|
|
Sarah |
Kyle |
|
|
|
Taylor |
Booth |
|
|
|
Nicolas |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Government Price Reporting
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
Medicaid Pricing and Rebates
---Average Manufacturer Price Calculations
Reimbursement for Innovative Products
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---Value-based Contracting and Communications
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Sarah |
Kyle |
|
|
|
Nicolas |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Capital Market Enhancements
---Accredited Investor definition
---SEC Small Business Forum
---SEC Rule 701
---PCAOB Audit Cost Increases
---Fair Investment Opportunities for Professional Experts Act (House Discussion Draft)
---H.R. 1343/S.488: Encouraging Employee Ownership Act
---H.R. 1312/S.416: Small Business Capital Formation Enhancement Act
Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
---Financial CHOICE Act (House Discussion Draft)
Proxy Advisory Services
---Impact of Policies on Small Public Companies
---Corporate Governance Reform and Transparency Act (House Discussion Draft)
---Financial CHOICE Act (House Discussion Draft)
Reform of SEC Regulation D
---Accredited Investor Certification
---Financial CHOICE Act (House Discussion Draft)
---H.R. 79/S. 588: HALOS Act
Sarbanes Oxley Section 404 (b)
---PCAOB Audit Cost Increases
---Small Issuer Exemption
---Financial CHOICE Act (House Discussion Draft)
---H.R. 1645: Fostering Innovation Act
Short Selling Transparency
Stock Exchange Tick Size
XBRL Exemption for Small Public Companies
---Financial CHOICE Act (House Discussion Draft)
---Small Company Disclosure Simplification Act (House Discussion Draft)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Jeanne |
Haggerty |
|
|
|
Shelly |
Mui-Lipnik |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Antibiotic & Diagnostic Tax Credit
---H.R. 1840: Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017
Biofuels (Non-Funding)
---Accelerated Depreciation of Biofuels Facilities Extension
---Production Tax Credit Extension
Capital Formation Investment Incentives
---Reform of Net Operating Loss Rules
---Reform of Passive Loss Rules
---An Act to Modify Net Operating Loss Carryforwards (House Discussion Draft)
Orphan Drug Act Tax Credit
Renewable Chemicals/Bio-based Products (Non-Funding)
---New Production Tax Credit
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, American Battle Monuments Commission
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Rina |
Singh |
|
|
|
Sarah |
Kyle |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Taylor |
Booth |
|
|
|
Nicolas |
Magallanes |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Drug Importation
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2018
---Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2018
---S.469: Affordable and Safe Prescription Drug Importation Act
---S.Amdt.174 to S.Con.Res.3
---S.Amdt.178 to S.Con.Res.3
Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
Intellectual Property International Enforcement
---India
---Saudi Arabia
Turkish Requirement for Localized Drug Manufacturing
UN High Level Commission on Access to Medicines
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kathleen |
Holcombe |
|
|
|
Matthew |
OMara |
|
|
|
Sarah |
Kyle |
|
|
|
Taylor |
Booth |
|
|
|
Nicolas |
Magallanes |
|
|
|
Joseph |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
AGR |
BUD |
CPT |
ENG |
FUE |
HOM |
MED |
TAX |
|
ANI |
CHM |
CSP |
FOO |
HCR |
MMM |
SMB |
TRD |
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |